23 Normanby Road
Notting Hill, VIC 3168
Australia
61 3 9548 7586
https://www.inoviq.com
Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Leearne Maree Hinch B.Sc., B.V.M.S., BSc., M.B.A., M.R.C.V.S. | Chief Executive Officer | 307,69k | N/D | N/D |
Mr. Mark Edwards BAcc, C.A., CA | CFO & Company Secretary | 115,53k | N/D | N/D |
Prof. Gregory Edward Rice BSc (Hons), GradDipMgt, MHA, Ph.D. | Chief Scientific Officer | 197,68k | N/D | N/D |
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
L'ISS Governance QualityScore di INOVIQ Ltd al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.